评估马利佐米、泊马度胺和低剂量地塞米松治疗复发难治性多发性骨髓瘤的1期临床试验(NPI-0052-107):最终研究结果
马利佐米(MRZ)是不可逆泛亚基蛋白酶体抑制剂,联合泊马度胺和低剂量地塞米松(PMD方案)治疗复发难治性多发性骨髓瘤。38例患者中未观察到剂量限制性毒性,确定0.5 mg/m2 MRZ为推荐2期剂量。总体缓解率为53%(19/36),临床获益率为64%(23/36)。
要点
- 38例复发难治性多发性骨髓瘤患者接受PMD方案治疗,未观察到剂量限制性毒性。
- 确定马利佐米推荐2期剂量为0.5 mg/m2静脉给药。
- 总体缓解率53%(19/36),临床获益率64%(23/36)。
核心结论
- PMD方案耐受性良好,在重度经治的高危复发难治性多发性骨髓瘤患者中显示出有前景的活性。
研究设计与样本
- 1期临床试验,纳入38例复发难治性多发性骨髓瘤患者,既往中位治疗线数为4(范围1-10),所有患者均接受过来那度胺和硼替佐米治疗。
- 静脉给予MRZ 0.3-0.5 mg/m2,2小时输注,第1、4、8、11天;泊马度胺3-4 mg,第1-21天;低剂量地塞米松5或10 mg,每28天周期的第1、2、4、5、8、9、11、12、15、16、22和23天。
主要发现
- 未观察到剂量限制性毒性,确定0.5 mg/m2 MRZ为推荐2期剂量。
- 最常见的治疗相关≥3级不良事件为:中性粒细胞减少(11/38例,29%)、肺炎(4/38例,11%)、贫血(4/38例,11%)和血小板减少(4/38例,11%)。
- 总体缓解率为53%(19/36),临床获益率为64%(23/36)。
临床怎么用
- 作者结论认为PMD方案在重度经治的高危复发难治性多发性骨髓瘤患者中耐受性良好并显示出有前景的活性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Marizomib (MRZ) is an irreversible, pan-subunit proteasome inhibitor (PI) in clinical development for relapsed/refractory multiple myeloma (RRMM) and glioma. This study analysed MRZ, pomalidomide (POM) and low-dose dexamethasone (Lo-DEX) [PMD] in RRMM to evaluate safety and determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D). Intravenous MRZ (0·3-0·5 mg/m2 ) was administered over 2 h on days 1, 4, 8, 11; POM (3-4 mg) on days 1-21; and Lo-DEX (5 or 10 mg) on days 1, 2, 4, 5, 8, 9, 11, 12, 15, 16, 22 and 23 of every 28-day cycle. Thirty-eight patients were enrolled that had received a median of 4 (range 1-10) prior lines of therapy; all patients received prior lenalidomide and bortezomib. No dose-limiting toxicities (DLTs) were observed and 0·5 mg/m2 MRZ was determined to be the RP2D. The most common treatment-related ≥Grade 3 adverse events were: neutropenia (11/38 patients: 29%), pneumonia (4/38 patients 11%), anaemia (4/38 patients; 11%) and thrombocytopenia (4/38 patients; 11%). The overall response rate and clinical benefit rate was 53% (19/36) and 64% (23/36), respectively. In conclusion, PMD was well tolerated and demonstrated promising activity in heavily pre-treated, high-risk RRMM patients.
引用
- Spencer A, Harrison S, Zonder J, et al. A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study results. Br J Haematol. 2017. PMID: 29076150. doi:10.1111/bjh.14987
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。